Will Complement Inhibition Be the New Target in Treating COVID-19–Related Systemic Thrombosis?
- 2 June 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 141 (22), 1739-1741
- https://doi.org/10.1161/circulationaha.120.047419
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, ChinaJAMA Cardiology, 2020
- Atypical haemolytic uraemic syndrome: a case report of a rare cause of reversible cardiomyopathyEuropean Heart Journal - Case Reports, 2020
- Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic MicroangiopathyThrombosis and Haemostasis, 2020
- Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus PathogenesismBio, 2018
- Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoVEmerging Microbes & Infections, 2018
- Severe Acute Respiratory Syndrome and Venous Thromboembolism in Multiple OrgansAmerican Journal of Respiratory and Critical Care Medicine, 2010